Forskning
Udskriv Udskriv
Switch language
Rigshospitalet - en del af Københavns Universitetshospital
Udgivet

Estrogen receptor, Progesterone receptor, HER2 status and Ki67 index and responsiveness to adjuvant tamoxifen in postmenopausal high-risk breast cancer patients enrolled in the DBCG 77C trial

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

DOI

  1. Measured and genetically predicted plasma YKL-40 levels and melanoma mortality

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Combining conventional therapy with immunotherapy: A risky business?

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Whole genome sequencing of breast cancer

    Publikation: Bidrag til tidsskriftReviewForskningpeer review

  2. Genome-wide association and transcriptome studies identify target genes and risk loci for breast cancer

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  • Ann S Knoop
  • Anne-Vibeke Lænkholm
  • Maj-Britt Jensen
  • Kirsten V Nielsen
  • Jørn Andersen
  • Dorte Nielsen
  • Bent Ejlertsen
  • Danish Breast Cancer Cooperative Group
Vis graf over relationer

BACKGROUND: The DBCG 77C trial compared one year of tamoxifen in postmenopausal, steroid-receptor unknown, high-risk breast cancer patients to no adjuvant systemic therapy. After a potential follow-up of 30years we report overall efficacy of the study and results according to subtypes subsequently assessed by immunohistochemistry and fluorescent in situ hybridisation (FISH).

METHODS: Between 1977 and 1982, 1716 postmenopausal patients with tumours larger than 5cm or positive axillary nodes were randomly assigned to no systemic therapy or tamoxifen 30mg daily for one year. Archival tumour tissue from 1515 patients was analysed and the hormone receptor positive (estrogen receptor (ER) and/or progesterone receptor (PR)) cancers were defined as luminal A if Ki67 low and HER2-negative; as luminal B if Ki67 high or HER2-positive; and otherwise as non-luminal-HER2 positive or triple negative.

FINDINGS: In the intent-to-treat (ITT) population one year of tamoxifen improved the disease-free-survival (DFS) (hazard ratio (HR)=0.87; 95% confidence interval (CI) 0.77-0.98), the Breast Cancer Recurrence Rate (BCRR) (HR=0.79; 0.69-0.90) and reduced the breast-cancer-specific-mortality (BCM) (HR=0.83; 0.73-0.93). BCRR were improved significantly by tamoxifen in luminal A (HR=0.66; 0.53-0.84) and luminal B/HER2- (HR=0.54; 0.39-0.74) but not in the other subsets, and with similar results for BCM with 30years follow-up.

INTERPRETATION: One year of treatment with tamoxifen significantly improves BCRR and BCM in postmenopausal patients with ER positive breast cancers. The relative benefit from tamoxifen was not significantly different in luminal A and B subtypes.

FUNDING: The Danish Breast Cancer Cooperative Group (DBCG) prepared the original protocol (DBCG 77C) and was the sponsor of the study. Funding was not provided to the participating departments. The biomarker study was supported by grants from the Clinical Institute, Odense University.

OriginalsprogEngelsk
TidsskriftEuropean journal of cancer (Oxford, England : 1990)
Vol/bind50
Udgave nummer8
Sider (fra-til)1412-21
Antal sider10
ISSN0959-8049
DOI
StatusUdgivet - maj 2014

ID: 44382103